Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market

Executive Summary

Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.

You may also be interested in...



Novo Nordisk Pays $1.80bn To Buy Emisphere

The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.

EU Firsts Beckon For Alnylam & Novo; Wins For A Raft Of Others

A plethora of new drugs moved closer to the EU market this week after the European Medicines Agency recommended that they should be approved.

COVID-19 Treatment Xevudy Wins UK Approval; Preclinical Data Shows Promise Against Omicron

New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel